Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA023870 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA023870, RRID:AB_1846459
- Product name
- Anti-CDR2
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CDR2, Gene description: cerebellar degeneration-related protein 2, 62kDa, Alternative Gene Names: CDR62, Yo, Validated applications: ICC, WB, Uniprot ID: Q01850, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references
Paraneoplastic Cerebellar Degeneration
Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity
Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration
Teixeira V, Singh K, Gama J, Celestino R, Carvalho A, Pereira P, Abreu C, Dantas T, Carter A, Gassmann R
2024
2024
Paraneoplastic Cerebellar Degeneration
Herdlevær I, Haugen M, Mazengia K, Totland C, Vedeler C
Neurology Neuroimmunology & Neuroinflammation 2021;8(2)
Neurology Neuroimmunology & Neuroinflammation 2021;8(2)
Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity
Panja D, Vedeler C, Schubert M
Neuropathology and Applied Neurobiology 2018;45(2):141-156
Neuropathology and Applied Neurobiology 2018;45(2):141-156
Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies
Raspotnig M, Haugen M, Thorsteinsdottir M, Stefansson I, Salvesen H, Storstein A, Vedeler C
Cancer Immunology, Immunotherapy 2017;66(11):1463-1471
Cancer Immunology, Immunotherapy 2017;66(11):1463-1471
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis
Schubert M, Panja D, Haugen M, Bramham C, Vedeler C
Acta Neuropathologica 2014;128(6):835-852
Acta Neuropathologica 2014;128(6):835-852
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration
Datta P, Eichler T, Totland C, Haugen M, Qvale T, Mazengia K, Storstein A, Haukanes B, Vedeler C
PLoS ONE 2013;8(6):e66002
PLoS ONE 2013;8(6):e66002
No comments: Submit comment
No validations: Submit validation data